Transcript CNS 2 anxiolytics

CNS DEPRESSANTS
Anti-Anxiety Agents
and Sedative-Hypnotics
1
INTRODUCTION
• Anxiety is an unpleasant state of tension,
apprehension or uneasiness from an unknown
source.
• Symptoms are similar to those of fear and is due to
sympathetic activation
• Symptoms of Chronic, severe, debilitating anxiety
requires treatment
• Hypnosis simply means sleep inducing
• All antianxiety drugs cause sedation, and
function as anxiolytic and hypnotic agents.
2
3
CLASSIFICATION
• Barbiturates
• Benzodiazepines
• Are the two major categories of sedativehypnotics
• Other anxiolytic drugs
• Benzodiazepine antagonists
• Nonbarbiturate sedatives
4
BENZODIAZEPINES (BDZs)
• Are the most widely used anxiolytic drugs
• Have replaced barbiturates in the treatment of
anxiety cos are more effective and safer.
5
Mech of action
• GABA-A receptors is the target for BDZs.
• It binds to a site on GABA-A called BDZ
receptors
• Binding of GABA to its receptor opens the
chloride channel causing hyperpolarization.
• MOA: binding of BDZs to a site on GABA-A
receptor potentiates the effect of GABA by ↑ing
the frequency of opening of chloride channel.
6
7
Benzodiazepines
•
•
•
•
•
•
•
•
•
•
DIAZEPAM
ALPRAZOLAM
LORAZEPAM
CLONAZEPAM
FLURAZEPAM
TEMAZEPAM
QUAZEPAM
MIDAZOLAM
ESTAZOLAM
TRIAZOLAM
8
ACTIONS
• Reduction of anxiety: at low doses and acts via
enhancing the effects of GABA by binding to
GABA-A receptors.
• Sedative and hypnotic: at higher doses via
binding to GABA-A and enhancing the effect of
GABA
• Anterograde amnesia: causes temporary
impairment of memory by binding to GABA-A
receptors.
• Anticonvulsant: used to treat epilepsy
9
•
• Muscle relaxant: at high doses
• All BDZs have neither anesthetic nor analgesic
property
10
Therapeutic uses
• Anxiety disorders: that accompanies
depression and schizophrenia.
• Panic disorder, phobias: alprazolam
• Muscular disorder: diazepam
• Amnesia
• Seizures: clonazepam, diazepam(grand mal and
status epilepticus)
• Clorazepate, chlordiazepoxide, diazepam,
oxazepam and lorazepam useful for treatment
11
of alcohol withdrawal
continuation
• Sleep disorders:
• Flurazepam: ↑es duration of sleep, ↓es
number of awakenings and its long
acting
• Temazepam: used in pts who
experience freq wakening
• Triazolam: used to induce sleep in pts
with insomnia.
12
PHARMACOKINETICS
• BDZs are rapidly and completely absorbed after
oral administration.
• Duration of action:
• Long acting BDZs (1-3days):clorazepate,
chlordiazepoxide, diazepam, flurazepam and
quazepam
• Intermediate acting(10-20 hours): alprazolam,
estazolam, lorazepam, temazepam
• Short-acting (3-8 hours): oxazepam, triazolam 13
PRECAUTIONS
• LIVER FAILURE (most BDZs).
• Some are not metabolized by the liver and so can
be given to pts with liver disease. It includes
Oxazepam, Temazepam, Lorazepam. These drugs are
not metabolized in liver. ( remember the first letters
OTL – Outside The Liver)
• All BDZs cross the placenta and may depress the
newborn if given before birth
• Alcohol and other CNS depressants enhance the
sedative-hypnotic effects of BDZs
• Should be avoided in pts with narrow angle
glaucoma
14
ADVERSE EFFECTS
• DROWSINESS, CONFUSION
• ATAXIA
• Cognitive impairment
• DEPENDENCE : PSYCHOLOGICAL,
PHYSICAL
WITHDRAWAL :
• ANXIETY, TENSION,CONFUSION,
REBOUND INSOMNIA (Triazolam)
15
Benzodiazepine antagonist
FLUMAZENIL
• GABA receptor antagonist
• Rapidly Reverses the effect of benzodiazepines.
• I.V. route.
• Used for treatment of BDZs poisoning
SE:
• Nausea, vomiting, agitation and dizziness.
16
OTHER ANXIOLYTIC DRUGS
• BUSPIRONE
• HYDROXYZINE
• ZOLPIDEM
17
OTHER ANXIOLYTICS - BUSPIRONE
• Site of action: binds to 5-HT1A receptor
subtype.
• No anticonvulsant activity.
• No interaction with benzodiazepine binding
sites
• No muscle relaxant properties and causes
minimal sedation
• Minimal adverse effects
• USED FOR GAD Generalized Anxiety
Disorders
• Slow onset of action
18
ZOLPIDEM
• ACTS ON BENZODIAZEPINE RECEPTORS though
not a BDZ.
• HYPNOTIC
• NO ANTI CONVULSANT
• NO MUSCLE RELAXTION
• ONSET OF ACTION – FAST
• HALF LIFE – SHORT ( 3 HOURS)
• SE: NIGHTMARES, GI UPSET, DAYTIME
DROWSINESS
19
Barbiturates
• Were formerly the mainstay of treatment used to
sedate the patient or to induce and maintain
sleep.
• Have been replaced by BDZs cos they induce
tolerance, physical dependence, severe
withdrawal symptoms and coma in toxic doses.
20
DRUGS
•
•
•
•
PHENOBARBITAL – LONG ACTING
PENTOBARBITAL
SECOBARBITAL
THIOPENTAL – ULTRA SHORT ACTING
( 20 MIN)
21
BARBITURATES
MECH OF ACTION :
• Bind to GABA-A receptors potentiating the effect
of GABA by prolonging the duration of chloride
channel opening.
22
Actions
• Anesthesia
• Treatment of seizures
• Sedative(low dose) and hypnotic agents(high
doses)
• Depression of CNS and can lead to coma and
death.
• Respiratory depression
• Induces P450 in the liver
23
• No analgesic action
Therapeutic uses
• Anesthesia: thiopental an ultra-short acting
barbiturate is used intravenously to induce
anesthesia.
• Anticonvulsant: phenobarbital used in the
long term management of tonic-clonic seizures,
status epilepticus
• Anxiety: used as sedatives to relieve anxiety,
nervous tension, insomnia at low doses
24
pharmacokinetics
• Readily cross the placenta and can depress the
fetus.
• Are metabolized by the liver except
phenobarbital
• Excreted in urine
25
ADVERSE EFFECTS
• Drowsiness
• CNS: Impaired concentration, sluggishness
• HANG OVER: Hynoptic doses
• METABOLISED IN LIVER
• CI : ACUTE INTERMITTENT PORPHYRIA
• DEPENDENCE:
• WITHDRAWAL SEVERE: MAY CAUSE DEATH26
Barbiturate poisoning
•
•
•
•
Severe depression of respiration
CVS depression
Shock
Treatment: artificial respiration,gastic lavage,
hemodialysis, alkalinzation of urine.
• No specific barbiturate antagonist available
28
NONBARBITURATE SEDATIVES
• Chloral hydrate
• Antihistamine
• ethanol
29
OTHER SEDATIVES
• ANTI HISTAMINES
CHLORAL HYDRATE
• SEDATIVE AND HYPNOTIC
• SE: GI UPSET
• TASTE CHANGES
• PREFERRED ROUTE : PER RECTAL
30
31
ETHANOL
•
•
•
•
•
•
Is a CNS depressant at high doses
Anxiolytic
Produces sedation
Hypnosis with increasing dosage.
Crosses the placenta
Metabolized in the liver first to acetaldehyde by
alcohol dehydrogenase and then to acetate by
acetaldehyde dehydrogenase
32
ALCOHOL METAB
33
CNS
CHR. EFFECT
• DEPRESSION, MEMORY LOSS
• RISK FOR SEIZURES
• WERNICKES – KORSAKOFFS
ENCEPHALOPATHY
• Metabolic effects: hypoglycemia, gout,
lactic acidosis
34
CVS :
• ACUTE : VASODILATION
• HIGH DOSES : VASOCONSTRICTION IN
HEART
• CHRONIC: MYOCARDIAL DEPRESSION
GIT :
• ACUTE : STIMULATES ACID
• HIGH : DIRECT IRRITATION
• CHRONIC: DIARRHOEA / CONSTIPATION,,
PANCREATITIS
35
• LIVER :
• CHR : CIRRHOSIS
• RESPIRATORY DEPRESSION
• CHRONIC :IMPOTENCE, TESTICULAR ATROPHY,
GYNAECOMASTIA
• PREGNANCY : FETAL ALCOHOL SYN.
• LOW IQ, MICROCEPHALY, FACIAL
ABNORMAILITIES.
36
37
continuation
• Elimination: kidney(MC), lung
• Alcohol withdrawal is treated with BDZs
38
Disulfiram
• Blocks the oxidation of acetaldehyde to
acetate by inhibiting acetaldehyde
dehydrogenase
• Results in the accum of acetaldehyde in the
blood causing flushing, tachycardia,
hyperventilation, nausea
• Used in pts seriously desiring to stop alcohol
ingestion.
39
OTHER ALCOHOLS
METHANOL :
• FORMS FORMIC ACID
• EFFECTS : BLINDNESS, SEVERE ACIDOSIS..
CNS IMPAIRMENT…
• Ethylene glycol: forms OXALIC ACID
• Side effect: acute tubular necrosis
40
41